Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

A. Rovellini, D. Sommariva, A. Branchi, F. Maraffi, C. Montalto, R. Gandini, A. Fasoli

Research output: Contribution to journalArticle

Abstract

Ninety-eight type 2 diabetic patients with hyperlipidaemia in stable metabolic control with diet alone (41) or diet plus hypoglycaemic agents (57) were divided into two groups: group 1 was put on treatment with slow release bezafibrate 400 mg a day, while group 2 was considered as control. In group 1, after 1 month of bezafibrate, serum triglycerides fell by 47% and cholesterol by 13%. HDL cholesterol showed a non-significant trend toward an increase. Fasting blood glucose significantly decreased by 6%, fructosamine and glycated haemoglobin by 5%. During OGTT, the area under the curve of both serum C-peptide and blood glucose showed a trend toward a decrease after bezafibrate. However, the difference did not reach statistical significance. Thirty-six patients continued the treatment with the drug for 4 months and 23 for 8 months, without further changes of the lipid pattern and glycaemic control. In the control group no significant variation of the lipid levels occurred and diabetic control slightly worsened during the study. Bezafibrate has been proved to be effective in the treatment of hyperlipidaemia in type 2 diabetic patients. The drug seems moreover to improve glycaemic control. The mechanism by which bezafibrate produces this latter effect remains to be elucidated, though an increase of peripheral insulin sensitivity might be suggested.

Original languageEnglish
Pages (from-to)237-245
Number of pages9
JournalPharmacological Research
Volume25
Issue number3
DOIs
Publication statusPublished - 1992

Fingerprint

Bezafibrate
Hyperlipidemias
Blood Glucose
Lipids
Fructosamine
Diet
C-Peptide
Glycosylated Hemoglobin A
Glucose Tolerance Test
Serum
Hypoglycemic Agents
Pharmaceutical Preparations
HDL Cholesterol
Area Under Curve
Insulin Resistance
Fasting
Triglycerides
Therapeutics
Cholesterol
Control Groups

Keywords

  • bezafibrate
  • diabetes mellitus
  • glucose metabolism
  • hyperlipidaemia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. / Rovellini, A.; Sommariva, D.; Branchi, A.; Maraffi, F.; Montalto, C.; Gandini, R.; Fasoli, A.

In: Pharmacological Research, Vol. 25, No. 3, 1992, p. 237-245.

Research output: Contribution to journalArticle

Rovellini, A. ; Sommariva, D. ; Branchi, A. ; Maraffi, F. ; Montalto, C. ; Gandini, R. ; Fasoli, A. / Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. In: Pharmacological Research. 1992 ; Vol. 25, No. 3. pp. 237-245.
@article{26b0ee3d88324cd89d475ee63f6c41e0,
title = "Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia",
abstract = "Ninety-eight type 2 diabetic patients with hyperlipidaemia in stable metabolic control with diet alone (41) or diet plus hypoglycaemic agents (57) were divided into two groups: group 1 was put on treatment with slow release bezafibrate 400 mg a day, while group 2 was considered as control. In group 1, after 1 month of bezafibrate, serum triglycerides fell by 47{\%} and cholesterol by 13{\%}. HDL cholesterol showed a non-significant trend toward an increase. Fasting blood glucose significantly decreased by 6{\%}, fructosamine and glycated haemoglobin by 5{\%}. During OGTT, the area under the curve of both serum C-peptide and blood glucose showed a trend toward a decrease after bezafibrate. However, the difference did not reach statistical significance. Thirty-six patients continued the treatment with the drug for 4 months and 23 for 8 months, without further changes of the lipid pattern and glycaemic control. In the control group no significant variation of the lipid levels occurred and diabetic control slightly worsened during the study. Bezafibrate has been proved to be effective in the treatment of hyperlipidaemia in type 2 diabetic patients. The drug seems moreover to improve glycaemic control. The mechanism by which bezafibrate produces this latter effect remains to be elucidated, though an increase of peripheral insulin sensitivity might be suggested.",
keywords = "bezafibrate, diabetes mellitus, glucose metabolism, hyperlipidaemia",
author = "A. Rovellini and D. Sommariva and A. Branchi and F. Maraffi and C. Montalto and R. Gandini and A. Fasoli",
year = "1992",
doi = "10.1016/S1043-6618(05)80072-6",
language = "English",
volume = "25",
pages = "237--245",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "3",

}

TY - JOUR

T1 - Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

AU - Rovellini, A.

AU - Sommariva, D.

AU - Branchi, A.

AU - Maraffi, F.

AU - Montalto, C.

AU - Gandini, R.

AU - Fasoli, A.

PY - 1992

Y1 - 1992

N2 - Ninety-eight type 2 diabetic patients with hyperlipidaemia in stable metabolic control with diet alone (41) or diet plus hypoglycaemic agents (57) were divided into two groups: group 1 was put on treatment with slow release bezafibrate 400 mg a day, while group 2 was considered as control. In group 1, after 1 month of bezafibrate, serum triglycerides fell by 47% and cholesterol by 13%. HDL cholesterol showed a non-significant trend toward an increase. Fasting blood glucose significantly decreased by 6%, fructosamine and glycated haemoglobin by 5%. During OGTT, the area under the curve of both serum C-peptide and blood glucose showed a trend toward a decrease after bezafibrate. However, the difference did not reach statistical significance. Thirty-six patients continued the treatment with the drug for 4 months and 23 for 8 months, without further changes of the lipid pattern and glycaemic control. In the control group no significant variation of the lipid levels occurred and diabetic control slightly worsened during the study. Bezafibrate has been proved to be effective in the treatment of hyperlipidaemia in type 2 diabetic patients. The drug seems moreover to improve glycaemic control. The mechanism by which bezafibrate produces this latter effect remains to be elucidated, though an increase of peripheral insulin sensitivity might be suggested.

AB - Ninety-eight type 2 diabetic patients with hyperlipidaemia in stable metabolic control with diet alone (41) or diet plus hypoglycaemic agents (57) were divided into two groups: group 1 was put on treatment with slow release bezafibrate 400 mg a day, while group 2 was considered as control. In group 1, after 1 month of bezafibrate, serum triglycerides fell by 47% and cholesterol by 13%. HDL cholesterol showed a non-significant trend toward an increase. Fasting blood glucose significantly decreased by 6%, fructosamine and glycated haemoglobin by 5%. During OGTT, the area under the curve of both serum C-peptide and blood glucose showed a trend toward a decrease after bezafibrate. However, the difference did not reach statistical significance. Thirty-six patients continued the treatment with the drug for 4 months and 23 for 8 months, without further changes of the lipid pattern and glycaemic control. In the control group no significant variation of the lipid levels occurred and diabetic control slightly worsened during the study. Bezafibrate has been proved to be effective in the treatment of hyperlipidaemia in type 2 diabetic patients. The drug seems moreover to improve glycaemic control. The mechanism by which bezafibrate produces this latter effect remains to be elucidated, though an increase of peripheral insulin sensitivity might be suggested.

KW - bezafibrate

KW - diabetes mellitus

KW - glucose metabolism

KW - hyperlipidaemia

UR - http://www.scopus.com/inward/record.url?scp=0026608876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026608876&partnerID=8YFLogxK

U2 - 10.1016/S1043-6618(05)80072-6

DO - 10.1016/S1043-6618(05)80072-6

M3 - Article

C2 - 1518767

AN - SCOPUS:0026608876

VL - 25

SP - 237

EP - 245

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 3

ER -